Search results
Paulson Wealth Management Inc. Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 6 days agoPaulson Wealth Management Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.3% in the 4th quarter, according ...
Hedge Funds are Bullish on This Gene Therapy Stock
Insider Monkey via Yahoo Finance· 6 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ ...
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks via Yahoo Finance· 3 days agoGilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might...
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in...
Benzinga· 4 days agoGilead Sciences, Inc. GILD, following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results ...
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Zacks via Yahoo Finance· 6 days agoGilead Sciences, Inc. GILD and partner Arcus Biosciences, Inc. RCUS announce new data from Cohort B...
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
Zacks via Yahoo Finance· 5 days agoStocks recently featured in the blog include: NextEra Energy, Inc. NEE, BP p.l.c. BP, Gilead ...
The City With the highest HIV/AIDS Rates in the US
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest...
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal...
Benzinga· 6 days agoGilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response ...
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention...
Benzinga· 4 days agoThe mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves...
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 7 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...